Xponance Inc. Sells 227 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Xponance Inc. decreased its position in Inspire Medical Systems, Inc. (NYSE:INSP) by 5.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 3,869 shares of the company’s stock after selling 227 shares during the quarter. Xponance Inc.’s holdings in Inspire Medical Systems were worth $787,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. HealthInvest Partners AB bought a new position in shares of Inspire Medical Systems during the 4th quarter valued at approximately $657,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Inspire Medical Systems by 14.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,408 shares of the company’s stock valued at $1,304,000 after purchasing an additional 785 shares during the last quarter. Sentry Investment Management LLC bought a new position in shares of Inspire Medical Systems during the 4th quarter valued at approximately $479,000. Sumitomo Mitsui Trust Holdings Inc. bought a new position in shares of Inspire Medical Systems during the 4th quarter valued at approximately $1,271,000. Finally, Valeo Financial Advisors LLC increased its position in shares of Inspire Medical Systems by 25.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 5,591 shares of the company’s stock valued at $1,137,000 after purchasing an additional 1,119 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.

Insider Buying and Selling

In related news, Director Jerry C. Griffin sold 554 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $198.05, for a total transaction of $109,719.70. Following the completion of the sale, the director now directly owns 9,744 shares in the company, valued at approximately $1,929,799.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Timothy P. Herbert sold 40,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $205.09, for a total transaction of $8,203,600.00. Following the completion of the sale, the chief executive officer now directly owns 63,658 shares in the company, valued at approximately $13,055,619.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jerry C. Griffin sold 554 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $198.05, for a total value of $109,719.70. Following the sale, the director now owns 9,744 shares of the company’s stock, valued at $1,929,799.20. The disclosure for this sale can be found here. Insiders sold 76,371 shares of company stock worth $15,664,278 in the last three months. 4.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on INSP shares. Morgan Stanley started coverage on Inspire Medical Systems in a research report on Tuesday, March 19th. They set an “overweight” rating and a $250.00 target price on the stock. Stifel Nicolaus reaffirmed a “hold” rating and issued a $210.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, January 2nd. KeyCorp started coverage on Inspire Medical Systems in a research report on Tuesday, February 6th. They issued an “overweight” rating and a $278.00 price objective on the stock. Royal Bank of Canada started coverage on Inspire Medical Systems in a research report on Friday, April 19th. They issued an “outperform” rating and a $285.00 price objective on the stock. Finally, Mizuho reaffirmed a “buy” rating and issued a $250.00 price objective on shares of Inspire Medical Systems in a research report on Wednesday, March 27th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Inspire Medical Systems presently has an average rating of “Moderate Buy” and an average price target of $272.20.

Inspire Medical Systems Trading Down 1.4 %

Shares of INSP stock opened at $231.01 on Friday. Inspire Medical Systems, Inc. has a twelve month low of $123.27 and a twelve month high of $330.00. The stock has a fifty day simple moving average of $206.65 and a two-hundred day simple moving average of $185.40.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Tuesday, February 6th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.53. Inspire Medical Systems had a negative return on equity of 3.93% and a negative net margin of 3.39%. The business had revenue of $192.51 million during the quarter, compared to analysts’ expectations of $186.75 million. During the same period in the prior year, the business earned $0.10 EPS. The business’s revenue for the quarter was up 39.6% compared to the same quarter last year. Equities research analysts predict that Inspire Medical Systems, Inc. will post -0.35 earnings per share for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.